News on Stocks in Our Portfolios
Sanofi misses on generic
competition. Sanofi
(SNY) said Q1 business
net income fell to €1.61B (-12% Y/Y) on revenue of €8.1B, missing estimates on
both the top and bottom line. The results largely reflected the expiration of
patents on Plavix and Eloxatin as well as U.S. generic competition for Avapro. All told, generic
competition cost the firm more than half a billion euros in the quarter. The
company also appointed two new executive committee members.
Becton Dickinson (BDX): Q1 EPS of
$1.44 beats by $0.08. Revenue of $2.0B (+3.7% Y/Y) beats by
$0.01B
Economics
This Week’s Data
The
March US trade balance came in well below consensus.
April nonfarm payrolls
grew 165,000 versus expectations of up 153,000; unemployment declined from 7.6%
to 7.5%.
Here
is another look at the ‘participation rate’ (medium):
Other
Politics
Domestic
Friday morning
humor (short):
International
FBI
report implicates Saudi government in 9/11 attack (medium):
No comments:
Post a Comment